Xbrane Biopharma (Sweden) Top Management
| XBRANE Stock | SEK 0.20 0.01 4.76% |
Xbrane Biopharma employs about 74 people. The company is managed by 10 executives with a total tenure of roughly 16 years, averaging almost 1.0 years of service per executive, having 7.4 employees per reported executive. Analysis of Xbrane Biopharma's management performance can provide insight into the company performance.
| Nina Ivers Insider Head HR |
| Maria Edebrink Insider Head Assurance |
Xbrane |
Xbrane Biopharma Management Team Effectiveness
The company has return on total asset (ROA) of (0.1313) % which means that it has lost $0.1313 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of (0.3703) %, meaning that it generated substantial loss on money invested by shareholders. Xbrane Biopharma's management efficiency ratios could be used to measure how well Xbrane Biopharma manages its routine affairs as well as how well it operates its assets and liabilities.Xbrane Biopharma Workforce Comparison
Xbrane Biopharma AB is rated first in number of employees category among related companies. The total workforce of Drug Manufacturers - Specialty & Generic industry is at this time estimated at about 1,451. Xbrane Biopharma holds roughly 74.0 in number of employees claiming about 5% of equities under Drug Manufacturers - Specialty & Generic industry.
Xbrane Biopharma Benchmark Summation
Operator |
The output start index for this execution was zero with a total number of output elements of sixty-one. Xbrane Biopharma Price Series Summation is a cross summation of Xbrane Biopharma price series and its benchmark/peer.
Xbrane Biopharma Notable Stakeholders
A Xbrane Biopharma stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Xbrane Biopharma often face trade-offs trying to please all of them. Xbrane Biopharma's stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Xbrane Biopharma's stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
| Siavash Bashiri | COO, Head of Biosimilars | Profile | |
| Nina Ivers | Head HR | Profile | |
| Maria Edebrink | Head Assurance | Profile | |
| Dina Jurman | Head of Clinical Affairs | Profile | |
| Anette Lindqvist | CFO Relations | Profile | |
| Martin mark | Chief Officer | Profile | |
| David Vikstrm | Chief Officer | Profile | |
| Associate Gier | CoFounder | Profile | |
| Samuel Wagner | CoFounder Board | Profile | |
| Erik Domines | G Counsel | Profile |
About Xbrane Biopharma Management Performance
The success or failure of an entity such as Xbrane Biopharma often depends on how effective the management is. Xbrane Biopharma management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Xbrane management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Xbrane management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
Xbrane Biopharma AB , a biopharmaceutical company, develops and manufactures biosimilars and generic long acting injectables. Xbrane Biopharma AB was founded in 2008 and is headquartered in Solna, Sweden. Xbrane Biopharma operates under Pharmaceuticals And Biosciences classification in Sweden and is traded on Stockholm Stock Exchange. It employs 35 people.
The data published in Xbrane Biopharma's official financial statements usually reflect Xbrane Biopharma's business processes, product offerings, services, and other fundamental events. But there are other numbers, ratios, or fundamental indicators derived from these statements that are easier to understand and visualize within the underlying realities that drive quantitative information of Xbrane Biopharma. For example, before you start analyzing numbers published by Xbrane accountants, it's critical to develop an understanding of what Xbrane Biopharma's liquidity, profitability, and earnings quality are in the context of the Healthcare space in which it operates.
Please note, the presentation of Xbrane Biopharma's financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Xbrane Biopharma's management is honest, while the outside auditors are strict and uncompromising. Whatever the case, the imprecision that can be found in Xbrane Biopharma's accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Xbrane Biopharma AB. Please utilize our Beneish M Score to check the likelihood of Xbrane Biopharma's management manipulating its earnings.
Xbrane Biopharma Workforce Analysis
Traditionally, organizations such as Xbrane Biopharma use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Xbrane Biopharma within its industry.Xbrane Biopharma Manpower Efficiency
Return on Xbrane Biopharma Manpower
| Revenue Per Employee | 155.9K | |
| Revenue Per Executive | 1.2M | |
| Net Loss Per Employee | 2.5M | |
| Net Loss Per Executive | 18.8M | |
| Working Capital Per Employee | 864.9K | |
| Working Capital Per Executive | 6.4M |
Check out Your Current Watchlist to better understand how to build diversified portfolios, which includes a position in Xbrane Biopharma AB. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in board of governors. You can also try the Positions Ratings module to determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance.
Complementary Tools for Xbrane Stock analysis
When running Xbrane Biopharma's price analysis, check to measure Xbrane Biopharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Xbrane Biopharma is operating at the current time. Most of Xbrane Biopharma's value examination focuses on studying past and present price action to predict the probability of Xbrane Biopharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Xbrane Biopharma's price. Additionally, you may evaluate how the addition of Xbrane Biopharma to your portfolios can decrease your overall portfolio volatility.
| Portfolio Comparator Compare the composition, asset allocations and performance of any two portfolios in your account | |
| My Watchlist Analysis Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like | |
| Aroon Oscillator Analyze current equity momentum using Aroon Oscillator and other momentum ratios | |
| Price Exposure Probability Analyze equity upside and downside potential for a given time horizon across multiple markets | |
| Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios |